Biotech Values

[DewDiligence]

MATN* reverse-merges into Oncotelic Inc.:

https://www.globenewswire.com/news-release/2019/04/18/1806348/0/en/Mateon-Enters-into-Merger-Agreement-with-Oncotelic.html

Mateon Therapeutics, Inc. and Oncotelic Inc., a privately-held, late clinical-stage cancer immunotherapy company, announced today that they have entered into a definitive agreement with respect to a merger, creating a publicly traded immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma.

…Assuming the conversion of all preferred shares, current Oncotelic stockholders would own 85% of the combined company, and current Mateon stockholders will own 15%.

*f/k/a OXGN.